Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Spiroindolones, a potent compound class for the treatment of malaria.

Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT.

Science. 2010 Sep 3;329(5996):1175-80. doi: 10.1126/science.1193225.

2.

Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials.

Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, Kirk K.

Cell Host Microbe. 2013 Feb 13;13(2):227-37. doi: 10.1016/j.chom.2012.12.006.

3.

Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4.

Turner H.

Future Med Chem. 2016;8(2):227-38. doi: 10.4155/fmc.15.177. Epub 2016 Jan 29. Review.

PMID:
26824174
4.

Microbiology. Is the tide turning for new malaria medicines?

Wells TN.

Science. 2010 Sep 3;329(5996):1153-4. doi: 10.1126/science.1194923. No abstract available.

PMID:
20813940
5.

Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.

Yeung BK, Zou B, Rottmann M, Lakshminarayana SB, Ang SH, Leong SY, Tan J, Wong J, Keller-Maerki S, Fischli C, Goh A, Schmitt EK, Krastel P, Francotte E, Kuhen K, Plouffe D, Henson K, Wagner T, Winzeler EA, Petersen F, Brun R, Dartois V, Diagana TT, Keller TH.

J Med Chem. 2010 Jul 22;53(14):5155-64. doi: 10.1021/jm100410f.

PMID:
20568778
6.

A Basis for Rapid Clearance of Circulating Ring-Stage Malaria Parasites by the Spiroindolone KAE609.

Zhang R, Suwanarusk R, Malleret B, Cooke BM, Nosten F, Lau YL, Dao M, Lim CT, Renia L, Tan KS, Russell B.

J Infect Dis. 2016 Jan 1;213(1):100-4. doi: 10.1093/infdis/jiv358. Epub 2015 Jul 1.

7.

Novel 4-aminoquinoline analogs highly active against the blood and sexual stages of Plasmodium in vivo and in vitro.

Sáenz FE, Mutka T, Udenze K, Oduola AM, Kyle DE.

Antimicrob Agents Chemother. 2012 Sep;56(9):4685-92. doi: 10.1128/AAC.01061-12. Epub 2012 Jun 18.

8.

Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum.

Vaidya AB, Morrisey JM, Zhang Z, Das S, Daly TM, Otto TD, Spillman NJ, Wyvratt M, Siegl P, Marfurt J, Wirjanata G, Sebayang BF, Price RN, Chatterjee A, Nagle A, Stasiak M, Charman SA, Angulo-Barturen I, Ferrer S, Belén Jiménez-Díaz M, Martínez MS, Gamo FJ, Avery VM, Ruecker A, Delves M, Kirk K, Berriman M, Kortagere S, Burrows J, Fan E, Bergman LW.

Nat Commun. 2014 Nov 25;5:5521. doi: 10.1038/ncomms6521.

9.

Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.

Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW, Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT, Winzeler EA.

Science. 2011 Dec 9;334(6061):1372-7. doi: 10.1126/science.1211936. Epub 2011 Nov 17.

10.

Antimalarial activity of endoperoxide compound 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol.

Sato A, Hiramoto A, Morita M, Matsumoto M, Komich Y, Nakase Y, Tanigawa N, Hiraoka O, Hiramoto K, Hayatsu H, Higaki K, Kawai S, Masuyama A, Nojima M, Wataya Y, Kim HS.

Parasitol Int. 2011 Sep;60(3):270-3. doi: 10.1016/j.parint.2011.04.001. Epub 2011 Apr 8.

PMID:
21501696
11.

Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials.

Flannery EL, McNamara CW, Kim SW, Kato TS, Li F, Teng CH, Gagaring K, Manary MJ, Barboa R, Meister S, Kuhen K, Vinetz JM, Chatterjee AK, Winzeler EA.

ACS Chem Biol. 2015 Feb 20;10(2):413-20. doi: 10.1021/cb500616x. Epub 2014 Nov 5.

12.

Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.

Nzila A, Rottmann M, Chitnumsub P, Kiara SM, Kamchonwongpaisan S, Maneeruttanarungroj C, Taweechai S, Yeung BK, Goh A, Lakshminarayana SB, Zou B, Wong J, Ma NL, Weaver M, Keller TH, Dartois V, Wittlin S, Brun R, Yuthavong Y, Diagana TT.

Antimicrob Agents Chemother. 2010 Jun;54(6):2603-10. doi: 10.1128/AAC.01526-09. Epub 2010 Mar 29.

13.

In Silico screening on the three-dimensional model of the Plasmodium vivax SUB1 protease leads to the validation of a novel anti-parasite compound.

Bouillon A, Giganti D, Benedet C, Gorgette O, Pêtres S, Crublet E, Girard-Blanc C, Witkowski B, Ménard D, Nilges M, Mercereau-Puijalon O, Stoven V, Barale JC.

J Biol Chem. 2013 Jun 21;288(25):18561-73. doi: 10.1074/jbc.M113.456764. Epub 2013 May 7.

14.

A class of potent antimalarials and their specific accumulation in infected erythrocytes.

Wengelnik K, Vidal V, Ancelin ML, Cathiard AM, Morgat JL, Kocken CH, Calas M, Herrera S, Thomas AW, Vial HJ.

Science. 2002 Feb 15;295(5558):1311-4.

15.

Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal.

Ranjitkar S, Schousboe ML, Thomsen TT, Adhikari M, Kapel CM, Bygbjerg IC, Alifrangis M.

Malar J. 2011 Apr 1;10:75. doi: 10.1186/1475-2875-10-75.

16.

Identification of a new chemical class of antimalarials.

Brunner R, Aissaoui H, Boss C, Bozdech Z, Brun R, Corminboeuf O, Delahaye S, Fischli C, Heidmann B, Kaiser M, Kamber J, Meyer S, Papastogiannidis P, Siegrist R, Voss T, Welford R, Wittlin S, Binkert C.

J Infect Dis. 2012 Sep 1;206(5):735-43. doi: 10.1093/infdis/jis418. Epub 2012 Jun 25.

17.

A novel multiple-stage antimalarial agent that inhibits protein synthesis.

Baragaña B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G, Ruecker A, Upton LM, Abraham TS, Almeida MJ, Pradhan A, Porzelle A, Martínez MS, Bolscher JM, Woodland A, Norval S, Zuccotto F, Thomas J, Simeons F, Stojanovski L, Osuna-Cabello M, Brock PM, Churcher TS, Sala KA, Zakutansky SE, Jiménez-Díaz MB, Sanz LM, Riley J, Basak R, Campbell M, Avery VM, Sauerwein RW, Dechering KJ, Noviyanti R, Campo B, Frearson JA, Angulo-Barturen I, Ferrer-Bazaga S, Gamo FJ, Wyatt PG, Leroy D, Siegl P, Delves MJ, Kyle DE, Wittlin S, Marfurt J, Price RN, Sinden RE, Winzeler EA, Charman SA, Bebrevska L, Gray DW, Campbell S, Fairlamb AH, Willis PA, Rayner JC, Fidock DA, Read KD, Gilbert IH.

Nature. 2015 Jun 18;522(7556):315-20. doi: 10.1038/nature14451.

18.

Identification of an antimalarial synthetic trioxolane drug development candidate.

Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FC, Chollet J, Dong Y, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang Y, Urwyler H, Wittlin S, Charman WN.

Nature. 2004 Aug 19;430(7002):900-4.

19.
20.

Detection of high levels of mutations involved in anti-malarial drug resistance in Plasmodium falciparum and Plasmodium vivax at a rural hospital in southern Ethiopia.

Mula P, Fernández-Martínez A, de Lucio A, Ramos JM, Reyes F, González V, Benito A, Berzosa P.

Malar J. 2011 Aug 2;10:214. doi: 10.1186/1475-2875-10-214.

Items per page

Supplemental Content

Write to the Help Desk